AI-Based Drug Discovery of TKIs Targeting L858R/T790M/C797S-Mutant EGFR in Non-small Cell Lung Cancer
Lung cancer has a high mortality rate, and non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Patients have been observed to acquire resistance against various anticancer agents used for NSCLC due to L858R (or Exon del19)/T790M/C797S-EGFR mutations. Therefore, next-generation...
Saved in:
Main Authors: | Geunho Choi (Author), Daegeun Kim (Author), Junehwan Oh (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Structure-activity exploration of a small-molecule allosteric inhibitor of T790M/L858R double mutant EGFR
by: Francesca Foschi, et al.
Published: (2023) -
Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFRWT, EGFRT790M, and EGFRL858R)
by: Mahmoud G. Abo Al-Hamd, et al.
Published: (2023) -
Feiyiliu Mixture sensitizes EGFRDel19/T790M/C797S mutant non-small cell lung cancer to osimertinib by attenuating the PRC1/Wnt/EGFR pathway
by: Jingjing Shi, et al.
Published: (2023) -
A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma
by: Muammar Fawwaz, et al.
Published: (2021) -
Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer
by: Si-Yang Maggie Liu, et al.
Published: (2023)